Contact

Gesgenerics and OWL: M&A biotech sector in June 2015


,
Integral service around a transaction
BY : Diego GutiérrezJuly Thu, 2015
Foreign biotechs are interested in Spanish companies. Gesgenéricos has been bought by Israel's Altan Pharma and the Basque company OWL has granted Galmed an option to buy up to 19.9 % of the company.

 

m&a biotech sector in June

Altan Pharma buys Gesgenerics

 The Irish Altan Phrama enters Spain with the acquisition of the pharmaceutical group GesGenéricos for €87.5M. "To finance the transaction, Altan has received €34.5m from the investment company Malin and a loan from Santander bank," says Diego Gutiérrez of Abra-Invest.

Altan is a pharmaceutical company that has recently been created by four professionals from the following backgrounds Abbott Laboratories. The acquisition of the GES group represents the realisation of the first milestone in Altan's long-term strategic plan to create a global specialty pharmaceutical company. The acquisition of GES will enable Altan to enter the injectable pharmaceuticals sector in Europe and selected Asian and Latin American markets.

 GESGenerics is a privately owned group of Spanish companies based in Madrid, which develops, manufactures and commercialises specialised injectable drugs for the hospital and healthcare provider market. GES has been offering the Spanish market a complete line of injectable drugs since 1985.

OWL signs agreement with Galmed Pharmaceuticals

The Basque biotech company OWL, which leads the market in the use of metabolomics for the development of liver disease diagnostics, has announced a licensing and research agreement and option to purchase an equity interest with Israel's Galmed Pharmaceuticals.

The agreement aims to develop a non-invasive test that will include a series of unique metabolomic biomarkers that will potentially predict the therapeutic response to Aramchol, a daily oral treatment for the treatment of non-alcoholic steatohepatitis.

 In addition, an agreement has been formalised to regulate Galmed's equity participation in OWL through the purchase of shares linked to 2 key milestones of the project. The first payment of €75,000 will be made upon completion of the interim analysis of the Arrest study scheduled for the first half of 2016 and the second payment of €100,000 will be made upon completion of the ARREST study. The expected investment in OWL will be €175,000, at the company's most recent valuation. Finally, OWL has granted Galmed an option to purchase up to 19.9 % of the company.

 

If you are looking for financing, please contact us. Call +34946024142 or fill in the contact form.

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu